A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
Clinical trial NCT01910181 · COMPLETED
Trial details
- NCT number
- NCT01910181
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2013-08-17
- Primary completion
- 2013-10-22
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.